Mark R Sullivan
Overview
Explore the profile of Mark R Sullivan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
927
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sullivan M, Rubin E
bioRxiv
. 2025 Jan;
PMID: 39764009
Drugs must accumulate at their target site to be effective, and inadequate uptake of drugs is a substantial barrier to the design of potent therapies. This is particularly true in...
2.
McGowen K, Funck T, Wang X, Zinga S, Wolf I, Akusobi C, et al.
bioRxiv
. 2024 Sep;
PMID: 39229117
is a pulmonary pathogen that exhibits intrinsic resistance to antibiotics, but the factors driving this resistance are incompletely understood. Insufficient intracellular drug accumulation could explain broad-spectrum resistance, but whether antibiotics...
3.
Commins N, Sullivan M, McGowen K, Koch E, Rubin E, Farhat M
Proc Natl Acad Sci U S A
. 2023 May;
120(22):e2302033120.
PMID: 37216535
() is a multidrug-resistant pathogen increasingly responsible for severe pulmonary infections. Analysis of whole-genome sequences (WGS) of demonstrates dense genetic clustering of clinical isolates collected from disparate geographic locations. This...
4.
Sullivan M, McGowen K, Liu Q, Akusobi C, Young D, Mayfield J, et al.
Nat Microbiol
. 2023 Jan;
8(3):481-497.
PMID: 36658396
Mycobacterium abscessus is an emerging pathogen causing lung infection predominantly in patients with underlying structural abnormalities or lung disease and is resistant to most frontline antibiotics. As the pathogenic mechanisms...
5.
Sullivan M, Darnell A, Reilly M, Kunchok T, Joesch-Cohen L, Rosenberg D, et al.
Nat Metab
. 2021 Nov;
3(11):1500-1511.
PMID: 34799701
Folate metabolism can be an effective target for cancer treatment. However, standard cell culture conditions utilize folic acid, a non-physiological folate source for most tissues. We find that the enzyme...
6.
Sullivan M, Rubin E, Dulberger C
mBio
. 2021 May;
12(3).
PMID: 34006655
(Mab) is an emerging pathogen that is highly tolerant to current antibiotic therapies, and the current standard of care has a high failure rate. Mycobacteriophages represent a promising alternative treatment...
7.
Sullivan M, Lewis C, Muir A
Bio Protoc
. 2021 Mar;
9(22):e3427.
PMID: 33654924
Cancer is a disease characterized by altered metabolism, and there has been renewed interest in understanding the metabolism of tumors. Even though nutrient availability is a critical determinant of tumor...
8.
Badeaux M, Rolig A, Agnello G, Enzler D, Kasiewicz M, Priddy L, et al.
Cancer Immunol Res
. 2021 Jan;
9(4):415-429.
PMID: 33500272
Metabolic dysregulation is a hallmark of cancer. Many tumors exhibit auxotrophy for various amino acids, such as arginine, because they are unable to meet the demand for these amino acids...
9.
Dalin S, Sullivan M, Lau A, Grauman-Boss B, Mueller H, Kreidl E, et al.
Cancer Res
. 2019 Sep;
79(22):5723-5733.
PMID: 31484670
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer deaths in the United States. The deoxynucleoside analogue gemcitabine is among the most effective therapies to treat PDAC, however, nearly...
10.
Mattaini K, Sullivan M, Lau A, Fiske B, Bronson R, Vander Heiden M
BMC Cancer
. 2019 Jul;
19(1):723.
PMID: 31331318
Background: Copy number gain of the D-3-phosphoglycerate dehydrogenase (PHGDH) gene, which encodes the first enzyme in serine biosynthesis, is found in some human cancers including a subset of melanomas. Methods:...